VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50% KRAS 15% ALK 5% HER2 3% 100% MET 4% unknown 22% ALK 7 ALK ALK 8 ALK ALK ALK ALK ALK ALK
OptiView ALK D5F3 3 ALK OptiView ALK D5F3 ALK 9-12 OptiView ALK D5F3 FISHALK 3 OptiView ALK D5F3 ALK + + = OptiView AMP D5F3 ALK D5F3 OptiView DAB OptiView ULTRA XT XT GX ALK OptiView ALK D5F34 FISH 4 OptiView ALK D5F3 OptiView ALK D5F3 ALKDAB NordiQC OptiView ALK D5F3 13
4 OptiView ALK D5F3 OptiView ALK D5F3 ALK ALK NMP ALK 2007 EML4-ALK ALK ALK ALK 14 OptiView ALK D5F3 ALK D5F3 - DAB H2O2 HN OH DAB HN H2O2 OH OH H2O2 OH OptiView DAB - ALK D5F3 - OptiView DAB - OptiView ALK D5F3 ALK D5F3 14 4 OptiView ALK D5F3 OptiView ALK D5F3 15 ALK ALK FISH 16 ALK OptiView ALK D5F3 OptiView OptiView OptiView ALK D5F3 5A4
OptiView ALK D5F3 5 ALK OptiView ALK D5F3 OptiView ALK D5F3 22900EZX00041000 518-113735 790-4794 ALK D5F3 RxDx 50 518-111182 790-4795 250 518-111427 760-700 OptiView DAB 250 518-113742 760-099 OptiView 50 XT, GX OptiView DAB Cell Conditioning Pre-Primary Peroxidase Inhibitor Antibody OptiView Univ Linker OptiView Multimer OptiView Amplification OV AMP H2O2, OV Amplifier OV AMP Multimer Counterstain Post Counterstain CC1 92min Selected 16 min 12 min 12 min Selected 8 min 8 min Hematoxylin, 4 min Bluing, 4 min ULTRA ULTRA ALK U VENTANA ALK D5F3 Antibody Primary Counterstain Post Counterstain VENTANA ALK AB 16 min EU/Other Negative Control Hematoxylin, 4 min Bluing, 4 min OptiView ALK D5F3 NordiQCALK IHC ALK DAB DAB ALK ALK
6 OptiView ALK D5F3 OptiView ALK D5F3 1 2 3ALK ALK ALK CD56 x20 x20
OptiView ALK D5F3 7 References 1., ganjoho.jp, 2012 2., zangankyo.ncc.go.jp, 2017 3. Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 Aug 2;448 7153 561-6. 4. Shaw AT, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10;27 26 4247-53. 5. Pao W, et al. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011 Feb;12 2 :175-80 6. Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol. 2010 Feb;40 2 101-6. 7. 2016 8. ALK 2, 9. XALKORI Crizotinib Package Insert. 2017 10. Thorne-Nuzzo T, et al. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. J Thorac Oncol. 2017 Jan 29. pii S1556-0864 17 30044-8. 11. ZYKADIA ceritinib Package Insert. 2017 12. Jean-Charles Soria, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer ASCEND-4 a randomised, open-label, phase 3 study. Lancet. 2017 March 4 389 13. http://www.nordiqc.org/downloads/assessments/45_14.pdf 14. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16 5 1561-71. 15. Murry W. et al. An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators. Journal of Thoracic Oncology. 2014 May;9 5 631-8 16. Greta Ali, et al. ALK Rearrangement in a Large Series of Consecutive Non Small Cell Lung Cancers. Arch Pathol Lab Med. 2014 Nov;138 11 1449-58.
108-0075 東京都港区港南 1-2-70 http://www.roche-diagnostics.jp カスタマーソリューションセンター 0120-600-152 VENTANA は ロシュ社の登録商標です 1078.TD.TMS.2000.PAB01-024A